115 related articles for article (PubMed ID: 26924499)
1. (67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity.
Sivapackiam J; Harpstrite SE; Prior JL; Mattingly S; Sharma V
Nucl Med Biol; 2016 Mar; 43(3):191-7. PubMed ID: 26924499
[TBL] [Abstract][Full Text] [Related]
2.
Sivapackiam J; Laforest R; Sharma V
Nucl Med Biol; 2018 Apr; 59():29-35. PubMed ID: 29454148
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity.
Sivapackiam J; Kabra S; Speidel S; Sharma M; Laforest R; Salter A; Rettig MP; Sharma V
PLoS One; 2019; 14(5):e0215579. PubMed ID: 31120912
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport.
Sivapackiam J; Harpstrite SE; Prior JL; Gu H; Rath NP; Sharma V
Dalton Trans; 2010 Jul; 39(25):5842-50. PubMed ID: 20505882
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier.
Sharma V; Prior JL; Belinsky MG; Kruh GD; Piwnica-Worms D
J Nucl Med; 2005 Feb; 46(2):354-64. PubMed ID: 15695797
[TBL] [Abstract][Full Text] [Related]
6. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
7. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
[TBL] [Abstract][Full Text] [Related]
8. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
[TBL] [Abstract][Full Text] [Related]
9. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo.
Sharma V; Beatty A; Wey SP; Dahlheimer J; Pica CM; Crankshaw CL; Bass L; Green MA; Welch MJ; Piwnica-Worms D
Chem Biol; 2000 May; 7(5):335-43. PubMed ID: 10801474
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
11. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
13. Metalloprobes: Fluorescence imaging of multidrug resistance (MDR1) P-Glycoprotein (Pgp)-mediated functional transport activity in cellulo.
Sundaram GS; Sharma M; Kaganov D; Cho J; Harpstrite SE; Sharma V
J Inorg Biochem; 2016 Jun; 159():159-64. PubMed ID: 27031494
[TBL] [Abstract][Full Text] [Related]
14. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
15. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
17. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
Ganguly S; Panetta JC; Roberts JK; Schuetz EG
Drug Metab Dispos; 2018 Jul; 46(7):1014-1022. PubMed ID: 29674491
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.
Hoque MT; Shah A; More V; Miller DS; Bendayan R
J Neurochem; 2015 Dec; 135(6):1113-22. PubMed ID: 26465636
[TBL] [Abstract][Full Text] [Related]
20. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
